Found 285 articles for: "biologics"
Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis
August 2018 | Volume 17 | Issue 8 | Original Article | 880 | Copyright © August 2018
Psoriasis is a chronic, immune-mediated inflammatory disease characterized by localized scaling and plaques associated with itching and pain. In some cases, topical therapies are effective to treat mi...
Read MoreA Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy
August 2018 | Volume 17 | Issue 8 | Original Article | 845 | Copyright © August 2018
Objective: To assess the effectiveness and safety of combining calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam with biologic therapies for patients with plaque psoriasis who have ...
Read MoreLong-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years
August 2018 | Volume 17 | Issue 8 | Original Article | 826 | Copyright © August 2018
Background: Due to the chronic nature of psoriasis, it is important to assess the sustained response of treatments over time. Objective: To assess the efficacy of continuous treatment with guselkumab...
Read MoreThe Importance of Early Treatment in Psoriasis and Management of Disease Progression
July 2018 | Volume 17 | Issue 7 | Original Article | 737 | Copyright © July 2018
Psoriasis is a chronic, immune-mediated, inflammatory disease that if left untreated can result in prolonged subclinical inflammation that affects a variety of organs, including the heart, liver, kid...
Read MoreCurrently Constrained, Dermatologists Are Ready for New Acne Therapies
June 2018 | Volume 17 | Issue 6 | Editorials | 686 | Copyright © June 2018
Acne is the most common skin condition in the United States, affecting 50 million Americans annually. The disease...
Read MoreDemographic and Tumor Characteristics of Patients Younger Than 50 Years With Nonmelanoma Skin Cancer Referred for Mohs Micrographic Surgery
May 2018 | Volume 17 | Issue 5 | Original Article | 499 | Copyright © May 2018
BACKGROUND: An increase in nonmelanoma skin cancer (NMSC) in younger patients has been reported. Many are treated with Mohs micrographic surgery (MMS). OBJECTIVE: Investigate patient and tumor charac...
Read MoreMulti-Center, Double-Blind, Vehicle-Controlled Clinical Trial of an Alpha and Beta Defensin-Containing Anti-Aging Skin Care Regimen With Clinical, Histopathologic, Immunohistochemical, Photographic, and Ultrasound Evaluation
April 2018 | Volume 17 | Issue 4 | Original Article | 426 | Copyright © April 2018
Background/Objectives: Anti-aging strategies utilizing stem cells are in the forefront. Alpha and beta defensins are natural immune peptides that have been shown to activate an LGR6-positive stem cell...
Read MoreDupilumab in the Treatment of Dyshidrosis: A Report of Two Cases of Dyshidrotic Eczema
March 2018 | Volume 17 | Issue 3 | Case Reports | 355 | Copyright © March 2018
Dyshidrotic eczema is a distinct entity, often considered on the spectrum of atopic dermatitis, that primarily effec...
Read MoreOnset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis
March 2018 | Volume 17 | Issue 3 | Original Article | 247 | Copyright © March 2018
BACKGROUND: The advent of biologics has improved patient outcomes in the treatment of moderate-to-severe psoriasis. The time it takes for patients to see clinically meaningful improvement is an import...
Read MoreSafety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials
February 2018 | Volume 17 | Issue 2 | Original Article | 200 | Copyright © February 2018
BACKGROUND: Injection-site reactions (ISRs) are reported with biologic therapies. The objective of this study was to comprehensively characterize ISRs among moderate-to-severe psoriasis patients tr...
Read MorePrevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis
February 2018 | Volume 17 | Issue 2 | Original Article | 187 | Copyright © February 2018
IMPORTANCE: While psoriasis (Ps) is mainly characterized as an adult disease, it can also ...
Read MoreIncreased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis
February 2018 | Volume 17 | Issue 2 | Original Article | 180 | Copyright © February 2018
BACKGROUND: Psoriasis (Ps) is a chronic inflammatory immune-mediated skin disease that has been identified as a risk factor for various conditions including neoplasms. OBJECTIVE: To compare prevalenc...
Read MoreCost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis
December 2017 | Volume 16 | Issue 12 | Original Article | 1246 | Copyright © December 2017
BACKGROUND: Newer psoriasis treatments can achieve greater levels of effcacy than older systemic therapies; however, current pso-riasis costs are substantial. We sought to estimate costs per additi...
Read MoreReal-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis
December 2017 | Volume 16 | Issue 12 | Original Article | 1240 | Copyright © December 2017
OBJECTIVE: To examine real-world use and patient outcomes with apremilast, an oral PDE4 inhibitor, in the dermatology practice set-ting for treatment of patients with moderate to severe plaque psor...
Read MoreThe Latest Drugs and Small Molecule Inhibitors for Skin and Hair
December 2017 | Volume 16 | Issue 12 | Original Article | 1224 | Copyright © December 2017
Biologic drugs, a novel class of agents engineered to target specifc mediators of infammation, and small-molecule inhibitors that pen-etrate the cell membrane to interact with targets inside a cell...
Read MoreCombining Topical Psoriasis Treatment to Enhance Systemic and Phototherapy: A Review of the Literature
December 2017 | Volume 16 | Issue 12 | Original Article | 1209 | Copyright © December 2017
Psoriasis is a chronic inflammatory skin disease that affects millions of people in the United States as well as worldwide. While there is currently no cure for psoriasis, many treatment options ar...
Read MoreEvaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis
October 2017 | Volume 16 | Issue 10 | Original Article | 1002 | Copyright © October 2017
BACKGROUND: Psoriasis is associated with increased risk of major adverse cardiovascular events (MACE). OBJECTIVES: Compare MACE risk with biologics vs topical/phototherapy use. METHODS: Psoriasis Lo...
Read MoreUnderstanding State Regulation of Biosimilars and Effect on Prescribers
October 2017 | Volume 16 | Issue 10 | Original Article | 995 | Copyright © October 2017
Biologics are a mainstay of treatment for many dermatologic conditions, however the high costs can be prohibitive for many patients. A growing market of biosimilar drugs is emerging with the hope of p...
Read MoreApremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis
October 2017 | Volume 16 | Issue 10 | Original Article | 957 | Copyright © October 2017
BACKGROUND: Combining narrowband UVB (NB-UVB) phototherapy with biologics has been shown to enhance the therapeutic response of plaque psoriasis patients. The objective of this study was to evaluate t...
Read MoreSecukinumab: Long-term Safety and Efficacy in Psoriasis
August 2017 | Volume 16 | Issue 8 | Supplement Individual Articles | 115 | Copyright © August 2017